DT-109 Reverses Severe Fatty Liver Disease by Repairing the Gut Barrier
TL;DR
An experimental glycine-based tripeptide called DT-109 reversed severe metabolic dysfunction–associated steatohepatitis (MASH) in animal studies by strengthening the gut barrier and lowering intestinal ammonia, disrupting the harmful gut-to-liver inflammatory loop; findings in mice and nonhuman primates point to a new gut-targeted therapy approach for MASH, with clinical trials needed to assess safety and effectiveness in people.
Topics:healthhealth-and-medicine#dt-109#fatty-liver-disease#gut-barrier#gut-liver-axis#health-and-medicine#mash
- Experimental drug reverses severe fatty liver disease by repairing the gut ScienceDaily
- New drug candidate treats severe fatty liver disease by improving gut health News-Medical
- Cure For Fatty Liver? Scientists Reveal Game-Changing Drug That Heals From The Inside News18
- Drug candidate treats severe fatty liver disease by protecting the gut in animal models Michigan Medicine
Want the full story? Read the original reporting
Read on ScienceDaily